Table 1.
Clinical and pathologic characteristics of patients with DCIS who underwent SLNDa
| Negative SLN (n=1102) |
Positive SLN findings (n=132) |
P valuec (Neg vs pos SLN) |
P valued (ITCs vs mets) |
||
|---|---|---|---|---|---|
| ITCs (n=66) |
Metastases b (n=66) |
||||
| Age, years | .001 | .168 | |||
| Mean | 54.9 | 52.8 | 50.4 | ||
| Median (range) | 54.0 (21–90) | 51.5 (32–76) | 49.0 (29–80) | ||
| Biopsy method e | .099 | .010 | |||
| Percutaneous only | 878 (90.1) | 42 (4.3) | 55 (5.6) | ||
| Excisional | 224 (86.5) | 24 (9.3) | 11 (4.2) | ||
| Biopsy histologic subtype | |||||
| Solid | 683 (90.1) | 35 (4.6) | 40 (5.3) | .250 | .380 |
| Cribriform | 563 (88.1) | 43 (6.7) | 33 (5.2) | .159 | .078 |
| Papillary | 276 (83.9) | 27 (8.2) | 26 (7.9) | <.001 | .859 |
| Comedonecrosis | 798 (89.1) | 52 (5.8) | 46 (5.1) | .656 | .232 |
| Reason for SLND | |||||
| High grade | 559 (89.9) | 30 (4.8) | 33 (5.3) | .515 | .601 |
| DCIS size >2 cm f | 548 (86.7) | 47 (7.4) | 37 (5.9) | .003 | .070 |
| Palpable tumor | 131 (81.9) | 13 (8.1) | 16 (10.0) | .001 | .528 |
| Microinvasion suspicion | 196 (82.4) | 19 (8.0) | 23 (9.7) | <.001 | .455 |
| Total mastectomy | 841 (88.7) | 52 (5.5) | 55 (5.8) | .222 | .505 |
| Total no. of biopsies g | .030 | .878 | |||
| Mean | 1.29 | 1.52 | 1.52 | ||
| Median (range) | 1 (0–5) | 1 (0–4) | 1 (0–4) | ||
| Total no. of surgeries h | .007 | <.001 | |||
| Mean | 1.31 | 1.65 | 1.23 | ||
| Median (range) | 1 (1–4) | 2 (1–3) | 1 (1–3) | ||
| Total no. of interventions i | <.001 | .011 | |||
| Mean | 2.60 | 3.17 | 2.74 | ||
| Median (range) | 2 (1–8) | 3 (2–6) | 2 (1–7) | ||
| Total needle localizations | .519 | .114 | |||
| Mean | 0.5 | 0.6 | 0.4 | ||
| Median (range) | 0 (0–4) | 0 (0–3) | 0 (0–3) | ||
| Final pathologic diagnosis | <.001 | <.001 | |||
| Pure DCIS | 851 (93.8) | 44 (4.9) | 12 (1.3) | ||
| Microinvasive cancer | 57 (83.8) | 6 (8.8) | 5 (7.4) | ||
| Invasive cancer | 194 (74.9) | 16 (6.2) | 49 (18.9) | ||
| Pathologic size of DCIS * | <.001 | .258 | |||
| Mean | 3.8 | 5.6 | 6.6 | ||
| Median (range) | 3.0 (0–19.0) | 4.3 (0.3–18.0) | 6.5 (0.1–20.0) | ||
| ER status * | .033 | .405 | |||
| Positive | 695 (89.6) | 37 (4.8) | 44 (5.7) | ||
| Negative | 227 (84.7) | 22 (8.2) | 19 (7.1) | ||
| Unknown | 180 (94.7) | 7 (3.7) | 3 (1.6) | ||
| PR status * | .029 | .837 | |||
| Positive | 525 (90.2) | 27 (4.6) | 30 (5.2) | ||
| Negative | 393 (85.8) | 32 (7.0) | 33 (7.2) | ||
| Unknown | 184 (94.8) | 7 (3.6) | 3 (1.5) | ||
| Modified BNG j* | .808 | .862 | |||
| I | 61 (91.0) | 3 (4.5) | 3 (4.5) | ||
| II | 349 (88.8) | 24 (6.1) | 20 (5.1) | ||
| III | 580 (88.4) | 36 (5.5) | 40 (6.1) | ||
| Unknown | 112 (94.9) | 3 (2.5) | 3 (2.5) | ||
| Follow-up time, months | .799 | .061 | |||
| Mean | 68.0 | 62.1 | 75.7 | ||
| Median (range) | 61.8 (0.7–171) | 55.7 (8.7–149) | 71.9 (8.6–165) | ||
BNG, Black’s Nuclear Grade; DCIS, ductal carcinoma in situ; ER, estrogen receptor; ITCs, isolated tumor cells; mets, metastases; no., number; PR, progesterone receptor; SLN, sentinel lymph node; SLND, SLN dissection.
Values in table are number of patients (percentage) unless otherwise indicated.
Metastases includes micrometastases and macrometastases.
Comparison between negative SLN group versus positive SLN group.
Comparison within group with positive SLN findings (isolated tumor cells versus SLN metastases).
Method was classified as excisional if the patient underwent 1 or more excisional or incisional biopsies.
Size is greatest measurable diameter of lesion or calcifications on mammography or ultrasonography.
All percutaneous biopsies.
All excisional biopsies and surgeries.
Sum of total biopsies and total surgeries.
Grade I, well differentiated; grade II, moderately differentiated; grade III, poorly differentiated.
Excluded unknown values in statistics calculations.